Article Type: Review Articles

Minimizing Signal Loss and Optimizing Pharmacovigilance in VAERS

Volume 2, No 2

Jessica Rose

An analysis of VAERS limitations proposes enhanced data cleaning, advanced signal detection and AI-driven causality assessment to modernize vaccine adverse event reporting.

Evidence-Based Medicine vs Physiology-Based Medicine: A False Dichotomy?

Volume 2, No 2

Santiago M. Herrero

A viewpoint contends that evidence-based and physiology-based medicine are complementary, outlining an integrated framework that merges population evidence with bedside physiology.

Pre-Existing Immunity to COVID-19: Overview and Implications — Part 3

Volume 2, No 2

Rachel Nicoll

Part 3 of this review discusses how non-COVID vaccines and other factors may confer pre-existing immunity to SARS-CoV-2, exploring evidence from observational and clinical studies.

The Myth of the ‘Correct’ Sample Size: Why Formula-Based Justification Misleads Researchers and Reviewers

(Errors and simulations that benefit no one and harm many, depriving them of time and energy)

Volume 2, No 1

L. Prieto-Faliente, C. Carezo Diaz, C. Morin-Barcena

This educational essay contends that formula-based sample-size calculations often mislead researchers and reviewers, arguing that multiple sample sizes can be valid and advocating pragmatic, resource-driven approaches over rigid numeric formulas.

Creatinine-Guided Furosemide Therapy: A Pathophysiological Framework for Precision Diuretic Use in Critically Ill Patients

Volume 2, No 1

Santiago M. Herrero

This review proposes a physiology-based dosing framework for furosemide therapy in critically ill patients, using serum creatinine as a surrogate to guide individualized diuretic dosing and improve safety and efficacy.

RNA:DNA Hybrids Survive Digestion in mRNA Vaccine Manufacturing

Volume 2, No 1

Kevin McKernan, Charles Rixey, Jessica Rose

This study analyzes residual DNA contamination in mRNA vaccines and shows that RNA:DNA hybrids resist DNase digestion during manufacturing, urging improved quality-control assays to quantify and reduce DNA impurities.

Pre-Existing Immunity to COVID-19: Overview and Implications – Part 2

Volume 2, No 1

Rachel Nicoll

Part two of this review explores how exposure to other viruses, parasites and the microbiome influences pre-existing immunity to COVID-19, examining cross-reactivity, protective mechanisms and the role of commensal bacteria.

A Prospective Clinical Trial Evaluating a Polyherbal Combination for the Treatment of Opioid Use Disorder

Volume 2, No 1

Matthew Halma, Sidra Hassaan, Jessica Rodriguez, Joseph Varon

This prospective clinical trial protocol proposes evaluating a polyherbal nutraceutical combination as an adjunct treatment for opioid use disorder, outlining the trial design and discussing the opioid crisis and rationale for integrating herbal medicine.

Considering the Safety of COVID-19 mRNA Vaccines in Patients with Aneuploidy

Volume 1, No 4

Martin J. McCaffrey

The advent of the mRNA-based COVID-19 vaccines heralds a transformation in the world of immunization. The use of mRNA to stimulate antigenic foreign protein synthesis by host cells, which triggers an immune reaction that repels future true infection, has been theorized for decades. The COVID-19 vaccines represent the first mass deployment of this genetic technology. Using modified mRNA sequences for the COVID-19 spike protein, delivered in a lipid nanoparticle vehicle, injection with the COVID-19 vaccine is intended to recruit host cells that manufacture the spike protein and generate an immune response that protects against future infection.

Preventing Cancer: The ROOT Protocols

Volume 1, No 4

Paul Marik, Justus Hope

In 2022, approximately 20 million new cancer cases and 9.7 million cancer deaths occurred worldwide. By 2050, new cases are projected to double, driven by population growth, aging, and increased exposure to risk factors. Up to 40% of cancers may be preventable by addressing lifestyle and environmental risk factors. Numerous nutraceuticals and repurposed drugs exhibit chemoprophylactic properties.